John Karanicolas
Overview
Explore the profile of John Karanicolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
3947
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Post S, Keohane C, Rossiter L, Kaplan A, Khowsathit J, Matuska K, et al.
ACS Infect Dis
. 2022 Jul;
8(7):1376.
PMID: 35801300
No abstract available.
12.
Topchu I, Pangeni R, Bychkov I, Miller S, Izumchenko E, Yu J, et al.
Cell Mol Life Sci
. 2022 May;
79(6):285.
PMID: 35532818
NSD1, NSD2, and NSD3 constitute the nuclear receptor-binding SET Domain (NSD) family of histone 3 lysine 36 (H3K36) methyltransferases. These structurally similar enzymes mono- and di-methylate H3K36, which contribute to...
13.
Karmakar S, Ramirez O, Paul K, Gupta A, Kumari V, Botti V, et al.
NAR Cancer
. 2022 May;
4(2):zcac015.
PMID: 35528200
Musashi 2 (MSI2) is an RNA binding protein (RBP) that regulates asymmetric cell division and cell fate decisions in normal and cancer stem cells. MSI2 appears to repress translation by...
14.
Ruggiero M, Malhotra S, Fenton A, Swint-Kruse L, Karanicolas J, Hagenbuch B
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328632
In the Na/taurocholate cotransporting polypeptide (NTCP), the clinically relevant S267F polymorphism occurs at a "rheostat position". That is, amino acid substitutions at this position ("S267X") lead to a wide range...
15.
Andrianov G, Ong W, Serebriiskii I, Karanicolas J
J Chem Inf Model
. 2021 Nov;
61(12):5967-5987.
PMID: 34762402
In early-stage drug discovery, the hit-to-lead optimization (or "hit expansion") stage entails starting from a newly identified active compound and improving its potency or other properties. Traditionally, this process relies...
16.
Bai N, Miller S, Andrianov G, Yates M, Kirubakaran P, Karanicolas J
J Chem Inf Model
. 2021 Feb;
61(3):1368-1382.
PMID: 33625214
Proteolysis-targeting chimaeras (PROTACs) are molecules that combine a target-binding warhead with an E3 ligase-recruiting moiety; by drawing the target protein into a ternary complex with the E3 ligase, PROTACs induce...
17.
Ruggiero M, Malhotra S, Fenton A, Swint-Kruse L, Karanicolas J, Hagenbuch B
J Biol Chem
. 2020 Nov;
296:100047.
PMID: 33168628
Conventionally, most amino acid substitutions at "important" protein positions are expected to abolish function. However, in several soluble-globular proteins, we identified a class of nonconserved positions for which various substitutions...
18.
Lan L, Liu J, Xing M, Smith A, Wang J, Wu X, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32784494
RNA-binding protein Musashi-1 (MSI1) is a key regulator of several stem cell populations. MSI1 is involved in tumor proliferation and maintenance, and it regulates target mRNAs at the translational level....
19.
Adeshina Y, Deeds E, Karanicolas J
Proc Natl Acad Sci U S A
. 2020 Jul;
117(31):18477-18488.
PMID: 32669436
With the recent explosion in the size of libraries available for screening, virtual screening is positioned to assume a more prominent role in early drug discovery's search for active chemical...
20.
Leman J, Weitzner B, Lewis S, Adolf-Bryfogle J, Alam N, Alford R, et al.
Nat Methods
. 2020 Jun;
17(7):665-680.
PMID: 32483333
The Rosetta software for macromolecular modeling, docking and design is extensively used in laboratories worldwide. During two decades of development by a community of laboratories at more than 60 institutions,...